{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.8","upperLimit":"65.7","value":"51.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"RBC TI: ≥56 Days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.6","upperLimit":"55.0","value":"40.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"RBC TI: ≥84 Days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.1","upperLimit":"47.5","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"RBC TI: ≥112 Days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.1","upperLimit":"78.9","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Platelet TI: ≥56 Days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.9","upperLimit":"65.1","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Platelet TI: ≥84 Days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.9","upperLimit":"65.1","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Platelet TI: ≥112 Days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Transfusion independence was defined as no transfusion for 56 consecutive days or more (84 and 112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 2 or the converse. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.","id":"OG000","title":"MDS or CMML: ASTX727 or IV Decitabine"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set included all participants who received any amount of study treatment. 'Overall number of participants analyzed' signifies those who were evaluable for this outcome measure. 'Number analyzed' signifies those subjects who were evaluable for this outcome measure in specified category.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2.7 years","title":"MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}